HER-2 negative

WATCH: @YAbdouMD, of @UNC_Lineberger, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer. #bcsm #oncology https://t.co/bm3XbNunzN (@OncLive)

In the phase 3 GLOW trial, CAPOX plus zolbetuximab significantly improved progression free survival and overall survival in patients with CLDN18.2+, HER2- untreated #GastricCancer or gastroesophageal junction adenocarcinoma @AstellasUS @mdmanishshah https://t.co/YYbLHhiyOq (@NatureMedicine)

⭐️ #ASCO23: "CAPItello-291 trial for Resistant HR+/HER2- Advanced Breast Cancer - Phase 3 Study with Hope Rugo, MD @hoperugo @UCSFCancer" 🔬Improved survival & well-tolerated adverse events in patients. #BreastCancer #cancercare 🎗️ [video] https://t.co/B4qiFs1ccT @OncoAlert (@oncologytube)

Trastuzumab deruxtecan exhibits the highest objective response rate in patients with HER2+ metastatic #BreastCancer, but clinical activity is also observed in patients with HER2- or non-expressing tumors @fermosele @FAndreMD @GustaveRoussy #BCSM https://t.co/xciHmNO1wQ (@NatureMedicine)

WATCH: A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors. @dradityabardia @DrVKGadi @jhaveri_komal @wadavidal #bcsm https://t.co/yMz2cyhcUb (@OncLive)

Selection and sequencing of CDK4/6 inhibitors in metastatic HR+/HER2- breast cancer hinge on the maturation of data in the first-line setting and beyond, and need to account for patient concerns and preferences. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/SxrWSHh8F9 (@OncLive)

Our novel finding on distinct mechanisms of resistance to palbociclib and abemaciclib in HR+ / HER2- MBC. Is there rationale for switching CDK4/6i after progression? @kandymarsy @KellyKhunt @MDAndersonNews @CR_AACR @HarmonyTurk https://t.co/BMmXIlJ3kt (@kandymarsy)

During this event, Claudine Isaacs, MD, discussed the role of #elacestrant for patients with ER+, HER2-negative breast cancer. #bcsm | @LombardiCancer @claudine_isaacs https://t.co/HV86Y63CKw (@TargetedOnc)

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan monotherapy in select patients with unresectable or metastatic HR–positive, HER2-negative breast cancer. @JavierCortesMD #bcsm https://t.co/jU6u7chlOD (@OncLive)

Check out Dr. Erica Mayer @elmayermd @DFCI_BreastOnc discussing #ASCO23 evERA #BreastCancer Phase 3 Study - Giredestrant + Everolimus vs. Exemestane + Everolimus in Pts With ER+/HER2- Locally Advanced or Metastatic BC #bcsm https://t.co/1F9i6Kclgx (@Sameh_VuMedi)

Elizabeth A. Mittendorf, MD, PhD, discussed the TROPiCS-02 trial, which evaluated sacituzumab govitecan in HR–positive, HER2-negative breast cancer. #bcsm | @EMittendorfMD @DanaFarber https://t.co/KFZ6dleKn1 (@TargetedOnc)

Single-agent sacituzumab govitecan has received a positive opinion from @EMA_News regarding its use in unresectable or metastatic HR–positive, HER2-negative breast cancer based on data from the phase 3 TROPiCS-02 study. @JavierCortesMD #bcsm https://t.co/urqbkNoe0v (@OncLive)

🔛 @Nader_Guilherme discussing @oncodistinct the #LOCATOR trial proposal in implementation Local ablative tx for pts w/ #oligometastatic HR+/HER2- #bcsm @OncoAlert @JulesBordet (@DMBranco)

New📰published: AMEERA-3: Randomized Phase II Study of Amcenestrant Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. @stolaney1 and colleagues. https://t.co/QqL6DtT4C7 (@DFCI_BreastOnc)

From #ASCO23, @MdCurioni, Catherine Harper-Wynne, Philipp Harter & @StintzingS report on novelties in oncogene driven #NSCLC, HR+/ HER2- #breastcancer, gynaecological malignancies & #colorectalcancer 👇 https://t.co/1SzDkzJ4v6 #LCSM #BCSM #GynCSM #CRCSM (@myESMO)

Changing Practice in HR+/HER2- metastatic breast cancer: our @Medscape symposium on ADCs held during #ASCO23 is now available online! @jhaveri_komal @dradityabardia https://t.co/NbzK1ooqp2 (@PTarantinoMD)

Gedatolisib + palbociclib & letrozole produced durable responses w/ comparable safety to that observed w/ palbociclib & letrozole alone in treatment-naïve patients withER-positive, HER2-negative advanced breast cancer @hoperugo @UCSFCancer #bcsm https://t.co/Hpc5ZFF5GJ (@OncLive)

📢Our new paper is out! Fecal microbiota composition is related to response to CDK4/6-inhibitors+ET in HR+/HER2- metastatic #breastcancer https://t.co/qSzLlKKVKC Thanks to #DanieleGenerali @curijoey @valerioiebba and all the team involved. Here the results in brief 👇🏻 (@FrancescoSche20)

Gedatolisib + palbociclib & letrozole produced durable responses w/ comparable safety to that observed w/ palbociclib & letrozole alone in treatment-naïve patients withER-positive, HER2-negative advanced breast cancer @hoperugo @UCSFCancer #bcsm https://t.co/D5Xk9qw1X0 (@OncLive)

all the metastatic hormone positive her2 negative breast cancers don’t benefit from CDK4/6 inhibitors in front line! Speaker: Barbara Pistilli #florencebreast23 @OncoAlert @acampsmalea @ChelainG @MartaPerachino @FatjonaKrajaMD @FrancicaPaola (@Dr_m_garousi)

@OncLive State of the Science Summit opens with the 💥, with @drsarahsam brilliantly covering one of the most controversial topics in breast oncology: what 1L regimen to choose for patients with HR+/HER2- metastatic breast cancer? #bcsm (@PTarantinoMD)

It’s really a shame if @AnthemBCBS is not approving ribociclib for 1st line metastatic ER+HER2- breast cancer. (@FelipeBatalini)

We continue our review of major takeaways from #ASCO23 Our takeaway for today is that HER3-DXd Phase 2 study offered tumor shrinkage for most heavily pretreated HER2- and HR+/HR- #mbc patients and produced a tolerable safety profile (presented by @ErikaHamilton9). #bcsm #bc (@ourmbclife)

Yes, the goal of this study is to provide a new treatment option for those with CLDN18.2 positive, HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma to improve treatment outcomes and survival. (@QuintionDulles3)

Recently published📰: A phase I trial of #palbociclib and #bosutinib with #fulvestrant in patients with metastatic HR+ HER2- #BreastCancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor by @FilipaLynce @EDBarrowsMD @juliecollinsmd @claudine_isaacs @ppohlmann_ et al (@DFCI_BreastOnc)

WATCH: @stolaney1, of @DanaFarber, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer. #bcsm https://t.co/aFwiSRwpDr (@OncLive)

Check out Dr. Michail Ignatiadis @MIgnatiadis @JulesBordet discussing #ASCO23 Primary Efficacy Analyses of NeoRHEA, #Neoadjuvant #Biomarker Research Study of Palbociclib w/Endocrine Therapy in Estrogen Receptor Positive/HER2- BC #bcsm #breastcancer @EORTC https://t.co/iwysbmWmEj (@Sameh_VuMedi)

Check out Dr. Virginia Kaklamani @VKaklamani @UTHealthSAMDA discussing #ASCO23 Oral #Elacestrant vs. SOC in ER+/HER2- Advanced or #mBC w/o Detectable #ESR1 Mutation (EMERALD) - Subgroup Analysis by Prior Duration of CDK4/6i + ET #bcsm #breastcancer #cdk46 https://t.co/SDTuK9Jxot (@Sameh_VuMedi)

.@stolaney1 reviewed how findings from the phase 3 TROPiCS-02 study highlight the ability of sacituzumab govitecan to improve patient outcomes over chemotherapy among those with HR+, HER2- metastatic breast cancer. #bcsm #ASCO23 | @ASCO @DanaFarber https://t.co/upHPLvtAUe (@CancerNetwrk)

Check out Dr. Sara Tolaney @stolaney1 @DFCI_BreastOnc discussing #ASCO23 TROPiCS-02 Phase 3 Study Final OS Analysis - Sacituzumab Govitecan in Pts With HR+/HER2- #mBC #bcsm #OncTwitter #OncEd #breastcancer #Biomarkers #PrecisionOncology https://t.co/giGo9yPxs5 (@Sameh_VuMedi)

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan for patients with HR+/HER2- metastatic #breastcancer based on data from the TROPiCS-02 study. #bcsm #ASCO2023 | @DanaFarber @stolaney1 @ASCO https://t.co/oNdgIgDFxn (@TargetedOnc)

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). @stolaney1 Summary: https://t.co/EhtJ4vYzX0 #ASCO23 #bcsm (@paspears88)

TROPiCS-02 trial: SG continues to show benefit vs TPC with additional follow up in HR+/HER2- MBC 35% ⬇️ in risk of progression 21% ⬇️ in risk of death ☑️benefit seen regardless of Trop2 expression and HER2 status(low vs null) @stolaney1 #bcsm #ASCO23 @OncoAlert (@YAbdouMD)

Breast Cancer Research: Final results of TROPiCS-02 reported at #ASCO23. Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer Read more ➡️ https://t.co/mBMz5ZnZox CC: @DFCI_BreastOnc @STolaney1 (@DanaFarberNews)

#ASCO23 Treatment algorithm for HR+/HER2- mBC From the excellent presentation by Dr. @StoverLab @OncoAlert https://t.co/IxomFfRoss (@dr_yakupergun)

@stolaney1 presents updated survival data for sacituzumab in HR+/HER2- #MBC: 3.3 mo ⬆️ OS benefit (21% ⬇️ in risk of death) regardless of Trop-2 expression and in both HER2 0 and low populations. #ASCO23 #bcsm (@drteplinsky)

TROPiCS-02: sacituzumab govitecan vs TPC in HR+/HER2- MBC Median follow-up 12.8 mo PFS 5.5 vs 4.0 mo, HR 0.65 OS (exploratory) 14.5 vs 11.2 mo, HR 0.79 Less benefit if no visceral mets, but small subgroup. ORR 21% vs 14% @stolaney1 @DanaFarber @DFCI_BreastOnc #ASCO23 #bcsm (@MVanMeterMD)

Excellent job discussing new approaches to 1L therapy for ER+/HER2- #bcsm @StoverLab #ASCO23 where prolonging survival with improving QoL should remain the major endpoint. (@antgiorda)

Hall D2, @ElisaAgostinett on stage to take questions following the poster discussion. She presented clinico-genomic data from the @BIGagainstBC AURORA molecular screening program on patients with HR+/HER2- MBC treated with CDK4/6 inhibitors #ASCO23 (@aftimosp)

Super @ElisaAgostinett on stage at #ASCO23 to present clinico-genomic data from #AURORA study in patients with HR+/HER2- advanced #BreastCancer treated with CDK4/6 inhibitors #ItalianPride @OncoAlert @BIGagainstBC @JulesBordet (@matteolambe)

ELAINE-2 study (N 29), all post CDK4/6i, ESR1-mutated selected HR+HER2- #bcsm lasofoxifene + abema ORR 55.6%, mPFS 56 weeks 💪. ELAINE 3 (NCT05696626) will compare LAS/Abema with Fulv/Abema. Watch out for dvt risk (N 3/29). #ASCO23 #postcdk46 (@antgiorda)

Subgroup Analysis Demonstrates Promising Activity With Elacestrant in ER+/HER2- Advanced or Metastatic Breast Cancer @VKaklamani @UTHealthSA @ASCO #ASCO23 https://t.co/rmYqTciu61 (@OncLive)